Key Points
- Michael David Garrison, EVP of Becton, Dickinson & Co., sold 1,610 shares on Jan. 15 at an average of $207.46 for $334,010.60, cutting his holding by 11.75% to 12,095 shares (about $2.51M).
- BDX raised its quarterly dividend to $1.05 (annualized $4.20, ~2.0% yield); the company beat quarterly EPS estimates ($3.96 vs. $3.92), set FY2026 guidance of 14.75–15.05 EPS, and carries a consensus analyst rating of "Hold" with an average target of $207.64.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 1,610 shares of the company's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Michael David Garrison also recently made the following trade(s):
- On Wednesday, December 17th, Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.03, for a total value of $123,302.87.
Becton, Dickinson and Company Price Performance
Shares of BDX opened at $207.16 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm has a market cap of $59.02 billion, a PE ratio of 35.53, a PEG ratio of 2.30 and a beta of 0.23. The firm's 50 day moving average price is $195.88 and its 200 day moving average price is $189.31. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $1.04. Becton, Dickinson and Company's payout ratio is currently 72.04%.
Analyst Ratings Changes
A number of equities analysts have recently commented on BDX shares. Bank of America lifted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a "neutral" rating in a research report on Monday, January 5th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, November 7th. Jefferies Financial Group lifted their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a "buy" rating in a research note on Wednesday, December 10th. Finally, Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $207.64.
Get Our Latest Report on BDX
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. SOA Wealth Advisors LLC. grew its position in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 95 shares in the last quarter. Activest Wealth Management lifted its position in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. Bell Investment Advisors Inc increased its position in shares of Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 128 shares during the period. Finally, Cornerstone Planning Group LLC raised its stake in shares of Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
